Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Rises By 9.8%

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 55,100 shares, a growth of 9.8% from the December 15th total of 50,200 shares. Based on an average daily volume of 224,100 shares, the short-interest ratio is presently 0.2 days. Currently, 10.3% of the company’s shares are sold short.

Bone Biologics Price Performance

NASDAQ:BBLG opened at $0.98 on Monday. The firm has a 50 day simple moving average of $1.11 and a 200-day simple moving average of $1.43. Bone Biologics has a 1-year low of $0.80 and a 1-year high of $4.74.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.